<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:chebi fb="11" ids="26333">Prostaglandin</z:chebi> (PG) E1 is a potent <z:chebi fb="1" ids="35620">vasodilator</z:chebi> on the peripheral vessels and also has an inhibitory action of platelet aggregation </plain></SENT>
<SENT sid="1" pm="."><plain>Thus it is expected that <z:chebi fb="0" ids="15544">PGE1</z:chebi> may be used for the treatment of <z:e sem="disease" ids="C0265110" disease_type="Disease or Syndrome" abbrv="">cerebral vasospasm</z:e> due to aneurysmal <z:hpo ids='HP_0002138'>subarachnoid hemorrhage</z:hpo> (SAH) </plain></SENT>
<SENT sid="2" pm="."><plain>Lipo-<z:chebi fb="0" ids="15544">PGE1</z:chebi>, <z:chebi fb="23" ids="18059">lipid</z:chebi> emulsified <z:chebi fb="0" ids="15544">PGE1</z:chebi> less destroyed in the lung, has much longer half life time in the circulation than <z:chebi fb="0" ids="15544">PGE1</z:chebi> which is rapidly inactivated in the lung </plain></SENT>
<SENT sid="3" pm="."><plain>A pilot study, examining the clinical effect of Lipo-<z:chebi fb="0" ids="15544">PGE1</z:chebi> on <z:e sem="disease" ids="C0265110" disease_type="Disease or Syndrome" abbrv="">cerebral vasospasm</z:e>, was performed </plain></SENT>
<SENT sid="4" pm="."><plain>Of 27 patients with a ruptured anterior circulation <z:hpo ids='HP_0002617'>aneurysm</z:hpo>, who were operated on at <z:hpo ids='HP_0011009'>acute</z:hpo> stage, 12 were treated with Lipo-<z:chebi fb="0" ids="15544">PGE1</z:chebi> and hypervolemic therapy (Lipo-<z:chebi fb="0" ids="15544">PGE1</z:chebi> treated group) and 15 with hypervolemic only (control group) </plain></SENT>
<SENT sid="5" pm="."><plain>After the <z:hpo ids='HP_0002617'>aneurysm</z:hpo> was clipped, Lipo-<z:chebi fb="0" ids="15544">PGE1</z:chebi>, containing 15 micrograms of <z:chebi fb="0" ids="15544">PGE1</z:chebi> was administered every 8 hours for 2 weeks </plain></SENT>
<SENT sid="6" pm="."><plain>The appearance and severity of symptomatic vasospasm were less in the Lipo-<z:chebi fb="0" ids="15544">PGE1</z:chebi> treated group than the control, and the outcome of the Lipo-<z:chebi fb="0" ids="15544">PGE1</z:chebi> treated patients with or without vasospasm improved significantly at 1 month follow-up examination </plain></SENT>
<SENT sid="7" pm="."><plain>The cerebral blood flow (CBF) measurements were performed three times, at first (1st), second to third (2nd) and fourth to sixth (3rd) week after SAH </plain></SENT>
<SENT sid="8" pm="."><plain>In the Lipo-<z:chebi fb="0" ids="15544">PGE1</z:chebi> treated group, the 1st CBF measurement was done before administration of Lipo-<z:chebi fb="0" ids="15544">PGE1</z:chebi> started and the 2nd examination was performed after the completion of administration.(ABSTRACT TRUNCATED AT 250 WORDS) </plain></SENT>
</text></document>